Skip to main content
. 2021 Mar 26;13:2805–2810. doi: 10.2147/CMAR.S292730

Figure 2.

Figure 2

Major meningeal response to lorlatinib, both at the internal frontal level (upper panel) and in the posterior fossa (lower panel, red arrows). (A) Meningeal progression to entrectinib. (B) Response to lorlatinib after six weeks of treatment.